Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Debt to Equity (2021 - 2026)

ADC Therapeutics has reported Debt to Equity over the past 6 years, most recently at -$0.53 for Q1 2026.

  • Quarterly results put Debt to Equity at -$0.53 for Q1 2026, down 11.91% from a year ago — trailing twelve months through Mar 2026 was -$0.53 (down 11.91% YoY), and the annual figure for FY2025 was -$0.62, down 10.79%.
  • Debt to Equity reached -$0.53 in Q1 2026 per ADCT's latest filing, up from -$0.62 in the prior quarter.
  • Across five years, Debt to Equity topped out at $14.99 in Q4 2022 and bottomed at -$0.86 in Q2 2024.
  • Median Debt to Equity over the past 5 years was -$0.57 (2025), compared with a mean of $0.81.
  • The largest annual shift saw Debt to Equity surged 1952.68% in 2022 before it crashed 105.07% in 2023.
  • Over 5 years, Debt to Equity stood at $14.99 in 2022, then plummeted by 105.07% to -$0.76 in 2023, then grew by 26.24% to -$0.56 in 2024, then dropped by 10.79% to -$0.62 in 2025, then increased by 13.95% to -$0.53 in 2026.
  • Business Quant data shows Debt to Equity for ADCT at -$0.53 in Q1 2026, -$0.62 in Q4 2025, and -$0.48 in Q3 2025.